Alert: Last Day to Access Our Research on Top 2 Bluechip Stocks
Here is the latest financial fact sheet of ZENITH DRUGS LTD.. For more details, see the ZENITH DRUGS LTD. quarterly results and ZENITH DRUGS LTD. share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.2 |
No. of shares | m | 17.15 |
1 Week | % | -1.0 |
1 Month | % | -4.4 |
1 Year | % | - |
52 week H/L | Rs | 114.5/52.8 |
No. of Mths Year Ending |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
ZENITH DRUGS LTD. EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | |||
Low | Rs | NA | NA | NA | |||
Sales per share (Unadj.) | Rs | 1,642.0 | 2,291.4 | 2,863.0 | |||
Earnings per share (Unadj.) | Rs | 76.7 | 78.2 | 128.8 | |||
Diluted earnings per share | Rs | 1.8 | 1.8 | 3.0 | |||
Cash flow per share (Unadj.) | Rs | 107.2 | 111.4 | 161.4 | |||
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | |||
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | |||
Avg Dividend yield | % | 0 | 0 | 0 | |||
Book value per share (Unadj.) | Rs | 241.0 | 302.3 | 431.1 | |||
Adj. book value per share | Rs | 5.6 | 7.1 | 10.1 | |||
Shares outstanding (eoy) | m | 0.40 | 0.40 | 0.40 | |||
Price / Sales ratio | x | 0 | 0 | 0 | |||
Avg P/E ratio | x | 0 | 0 | 0 | |||
P/CF ratio (eoy) | x | 0 | 0 | 0 | |||
Price / Book Value ratio | x | 0 | 0 | 0 | |||
Dividend payout | % | 0 | 0 | 0 | |||
Avg Mkt Cap | Rs m | 0 | 0 | 0 | |||
Total wages/salary | Rs m | 24 | 28 | 39 |
ZENITH DRUGS LTD. INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 657 | 917 | 1,145 | |||
Other income | Rs m | 1 | 10 | 12 | |||
Total revenues | Rs m | 658 | 927 | 1,157 | |||
Gross profit | Rs m | 72 | 70 | 100 | |||
Depreciation | Rs m | 12 | 13 | 13 | |||
Interest | Rs m | 15 | 22 | 26 | |||
Profit before tax | Rs m | 46 | 44 | 72 | |||
Minority Interest | Rs m | 0 | 0 | 0 | |||
Prior Period Items | Rs m | 0 | 0 | 0 | |||
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | |||
Tax | Rs m | 15 | 13 | 21 | |||
Profit after tax | Rs m | 31 | 31 | 52 | |||
Gross profit margin | % | 11.0 | 7.6 | 8.7 | |||
Effective tax rate | % | 33.3 | 29.0 | 28.5 | |||
Net profit margin | % | 4.7 | 3.4 | 4.5 |
ZENITH DRUGS LTD. BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 358 | 535 | 839 | |||
Current liabilities | Rs m | 294 | 466 | 718 | |||
Net working cap to sales | % | 9.9 | 7.6 | 10.6 | |||
Current ratio | x | 1.2 | 1.1 | 1.2 | |||
Inventory Days | Days | 8 | 8 | 7 | |||
Debtors Days | Days | 1,300 | 1,277 | 1,572 | |||
Net fixed assets | Rs m | 107 | 151 | 140 | |||
Share capital | Rs m | 4 | 4 | 4 | |||
"Free" reserves | Rs m | 92 | 117 | 168 | |||
Net worth | Rs m | 96 | 121 | 172 | |||
Long term debt | Rs m | 73 | 96 | 84 | |||
Total assets | Rs m | 465 | 686 | 979 | |||
Interest coverage | x | 4.1 | 3.0 | 3.7 | |||
Debt to equity ratio | x | 0.8 | 0.8 | 0.5 | |||
Sales to assets ratio | x | 1.4 | 1.3 | 1.2 | |||
Return on assets | % | 9.8 | 7.8 | 8.0 | |||
Return on equity | % | 31.8 | 25.9 | 29.9 | |||
Return on capital | % | 36.0 | 30.7 | 38.5 | |||
Exports to sales | % | 0 | 0 | 0 | |||
Imports to sales | % | 0 | 0 | 0 | |||
Exports (fob) | Rs m | 0 | 0 | 0 | |||
Imports (cif) | Rs m | 0 | 0 | 0 | |||
Fx inflow | Rs m | 0 | 0 | 0 | |||
Fx outflow | Rs m | 0 | 0 | 0 | |||
Net fx | Rs m | 0 | 0 | 0 |
ZENITH DRUGS LTD. CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -9 | 52 | -44 | |||
From Investments | Rs m | -14 | -52 | 1 | |||
From Financial Activity | Rs m | 29 | 12 | 49 | |||
Net Cashflow | Rs m | -2 | 12 | 6 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Sandeep Bhardwaj | COMP SEC: Sakshi Bhawsar | YEAR OF INC: 2000 | NSE CODE: 100072 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare ZENITH DRUGS LTD. With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Asian share markets are mixed today as investors awaited China trade data to gauge the health of the Chinese economy.